bioecon Member area
Technology · Health & biomedicine / Therapeutics & platforms

Automated Formulated Lytic Bacteriophage Cocktails for Antimicrobial Resistance (AMR)

Robotic high-throughput screening and formulation of multi-strain lytic bacteriophage cocktails targeting distinct bacterial surface receptors to eliminate superbugs without resistance development.

Medicine & Pharmaceuticals Maturity 7/9 Risk: medium Pharma & biologics Advanced therapies US · EU · CN verified 2026-11-15 · 6 Sources (2 independent)

1 · What it gives

Automated Formulated Lytic Bacteriophage Cocktails for Antimicrobial Resistance (AMR) represents a cornerstone in global infectious disease defense and preventive immunotherapy, encompassing multivalent polysaccharide-protein conjugates, viral vectors, therapeutic cancer vaccines, and anti-infective phage platforms. By converting poorly immunogenic T-cell-independent antigens into robust, durable T-cell-dependent immune responses with immunological memory, the technology has eradicated major bacterial pathogens and provides proactive pandemic preparedness. Industrial bioprocess engineering coordinates bacterial/viral propagation, chemical activation, carrier protein conjugation, and immunological adjuvant compounding.

The operational spectrum encompasses large-scale microbial fermentation (e.g., Streptococcus pneumoniae, Neisseria meningitidis, or engineered E. coli), continuous lysis, and polysaccharide purification via tangential flow filtration. Polysaccharide chains undergo size-controlled microfluidic homogenization before cyanylation (using CDAP) or periodate activation, followed by covalent coupling to detoxified carrier proteins (such as CRM197, tetanus toxoid, or outer membrane vesicles). Purification utilizes 100–300 kDa ultrafiltration and size-exclusion chromatography, yielding conjugate purities >95% with free unconjugated polysaccharide <5%, followed by sterile formulation with advanced adjuvant systems (alum, MF59, QS-21).

The key directions of this technology are:

  1. Controlled Polysaccharide Activation for Automated Formulated Lytic Bacteriophage Cocktails for Antimicrobial Resistance (AMR): Implementing CDAP (1-cyano-4-dimethylaminopyridinium tetrafluoroborate) cyanylation to activate hydroxyl groups without depolymerizing native polysaccharide epitopes.
  2. Carrier Protein Conjugation & Cross-Linking: Coupling activated antigens to recombinant CRM197 or tetanus toxoid under controlled stoichiometry to maximize T-cell-dependent B-cell priming.
  3. Advanced Adjuvant Emulsion & Liposome Formulation: Compounding antigens with squalene-in-water nanoemulsions (MF59) or liposomal saponin combinations (AS01) to induce broad mucosal and systemic titers.
  4. Lyophilized Cold-Chain Independence: Developing spray-freeze-dried or trehalose-stabilized solid formulations maintaining vaccine potency at ambient temperatures (up to 40°C) for global distribution.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: High-Density Microbial Fermentation           │
│  (Pathogen culture, fed-batch, dissolved oxygen control│
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Lysis, Benzonase Digestion & TFF Extraction   │
│  (Enzymatic DNA/RNA clearance, 100-300 kDa diafiltr.)  │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: Chemical Activation & Carrier Conjugation     │
│  (CDAP activation, CRM197 coupling, free antigen <5%)  │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: Size-Exclusion & Hydrophobic Interaction Pur. │
│  (Separation of high-MW conjugates, endotoxin removal) │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Adjuvant Compounding & Sterile Fill-Finish    │
│  (Alum/nanoemulsion blending, 0.22 um filter, vials)   │
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Pathogen Strain Cultivation & BankingHigh-density fermentation of bacterial or viral production strains under Biosafety Level (BSL-2/3) containment.In: Cryopreserved seed stock, defined animal-free media, automated bioreactors.
Out: High-titer crude harvest broth containing target polysaccharide/antigen.
Cell Lysis & Primary PurificationDetergent or mechanical microfluidic cell disruption followed by Benzonase nuclease treatment to digest host nucleic acids.In: Crude harvest, Benzonase endonuclease, depth filtration cassettes.
Out: Clarified antigen-rich lysate free of genomic DNA contaminants.
Polysaccharide Activation & ConjugationControlled activation using CDAP or sodium periodate, followed by covalent linkage to CRM197 or recombinant protein carriers.In: Purified polysaccharide, carrier protein, CDAP cyanylating reagent.
Out: Covalently linked macromolecular conjugate reaction pool.
Conjugate Polishing & Free Antigen RemovalTangential flow ultrafiltration (300 kDa PES) and hydrophobic interaction chromatography removing unconjugated free polysaccharide.In: Crude conjugate, ammonium sulfate buffer, ultrafiltration cassettes.
Out: Purified conjugate drug substance with free polysaccharide < 5%.
Adjuvant Blending & Sterile Vial FillingCompounding with aluminum hydroxide or squalene emulsions, terminal sterile 0.22 um filtration, and automated filling into glass vials.In: Conjugate drug substance, adjuvant suspension, USP Type I vials.
Out: Final sterile multi-dose or single-dose vaccine product.

Cross-cutting technologies of the sector:

  • Multi-Angle Light Scattering (SEC-MALS): Absolute molecular weight profiling determining size distribution and polydispersity of high-molecular-weight vaccine conjugates.
  • Endotoxin & Pyrogen Testing (LAL / MAT): Recombinant factor C fluorometry and monocyte activation testing guaranteeing bacterial endotoxin levels strictly below pharmacopeial limits.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 4 steps

  1. 1
    Pathogen receptor profiling
    Isolation of clinical MDR strain and automated optical profiling of surface LPS/OMP targets.
  2. 2
    Biobank phage matching
    Robotic liquid handlers screen thousands of sequenced lytic phages for clear plaque lysis.
  3. 3
    Multi-receptor cocktail blendingFormulation & blending
    Formulating 3-5 distinct phages binding different surface sites to prevent bacterial escape.
  4. 4
    Endotoxin purificationPurification & downstream
    Ultrafiltration and phase separation reducing bacterial endotoxins below 5 EU/mL for IV use.

4 · Who delivers

Matched suppliers (matched automatically)

SyntBioLab Inc.CanadaResearch / RTOactive
IntralytixUnited StatesResearch / RTOactive
Bionatur Invernaderos Biológicos de MéxicoMexicoProduceractive
Biodx.coSouth AfricaProduceractive
PhageguardNetherlandsProduceractive
Tsingke BiotechnologyChinaProduceractive
Caladan BioUnited StatesProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Eliava🇺🇸 United StatesSpecialized Modality & Process PlatformIndustrial scalable manufacturing & QbD validationcommercial
Adaptive🇺🇸 United StatesSpecialized Modality & Process PlatformIndustrial scalable manufacturing & QbD validationcommercial
Biomx🇺🇸 United StatesSpecialized Modality & Process PlatformIndustrial scalable manufacturing & QbD validationcommercial
Microgen🇺🇸 United StatesSpecialized Modality & Process PlatformIndustrial scalable manufacturing & QbD validationcommercial
Pipeline Overview🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical
Programs🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical
Pipelines · CreatiPhage🇺🇸 United StatesProprietary Therapeutics & Process InfrastructureIndustrial scalable manufacturing & QbD validationclinical

5 · Rules & route to market

United States

FDA CBER oversight, BARDA pandemic funding, and CDC schedules#

  • FDA CBER Vaccine Standards: Strict clinical efficacy, lot-to-lot consistency, and potency assay requirements under CBER biologic regulations.
  • BARDA Strategic National Stockpile: Federal emergency preparedness funding supporting rapid-response vaccine manufacturing and surge capacity.
  • CDC Advisory Committee (ACIP) Recommendations: Rapid pediatric and adult immunization schedule adoption driving nationwide commercial scale.

European Union

EMA centralized evaluation, WHO collaborative hubs, Swiss quality#

  • European Vaccine Manufacturing Hubs: Long-established commercial production campuses across France, Belgium, and Germany supplying global immunization campaigns.
  • EMA Official Control Authority Batch Release (OCABR): Independent national control laboratory testing of each commercial batch prior to market release.
  • Global Health Initiatives: CEPI and Gavi partnerships headquartered in Geneva driving development of disease-X prototype platforms and equitable access.

China

National Immunization Program, NMPA pre-qualification, mega-capacity#

  • NMPA Priority Review & National Procurement: Fast-track clinical review and volume-based procurement driving massive scale for innovative vaccines.
  • Global WHO Pre-Qualification (PQ): Top Chinese manufacturers (Sinopharm, Sinovac, CanSino) achieving WHO pre-qualification for international supply.
  • High-Capacity Vaccine Centers: State-of-the-art biomanufacturing campuses in Beijing, Wuhan, and Shanghai with annual capacities exceeding billions of doses.

6 · Money: tenders & grants

GrantAgriculture and Food Research Initiative Competitive Grants Program Education and Workforce Development
National Institute of Food and Agriculture · United States
Dec 31, 2026
38 days
GrantAutomated Scientific Discovery – Food (RAISE pilot)
European Commission · EU
Feb 2, 2027
71 days
GrantBlueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the …
National Institutes of Health · United States
Aug 18, 2027
268 days
GrantCHIPS Research and Development Office (CRDO) Broad Agency Announcement (BAA)
National Institute of Standards and Technology · United States
Sep 30, 2029
1042 days
GrantDOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural …
Defense Health Agency Contracting Activity - DHACA · United States
Sep 30, 2027
311 days

7 · Tech stack & innovations

  1. Antigenic Carrier Architecture in Automated Formulated Lytic Bacteriophage Cocktails for Antimicrobial Resistance (AMR):
    • Utilizes non-toxic diphtheria toxin mutant CRM197 or tetanus toxoid containing dense CD4+ T-cell helper epitopes.
    • Triggers robust germinal center B-cell activation, immunoglobulin class switching to IgG1/IgG3, and long-term immunological memory.
  2. Controlled CDAP Cyanylation Chemistry:
    • 1-cyano-4-dimethylaminopyridinium tetrafluoroborate converts polysaccharide hydroxyls into cyanate esters under mild conditions (pH 9.0).
    • Forms stable isourea covalent bonds with carrier protein lysine residues while eliminating toxic cyanogen bromide byproducts.
  3. Ultra-High-Molecular-Weight Tangential Flow Filtration:
    • 300 kDa cut-off polyethersulfone membranes operated under controlled transmembrane pressure (<1.0 bar).
    • Delivers complete separation of heavy conjugated molecules (>1,000 kDa) from unreacted low-molecular-weight free polysaccharides.

Sources 6 · 2 independent · 4 producer sites

Independent sources 2

  1. www.nature.com research checked 2026-11-15
  2. link.springer.com research checked 2026-11-15

Producers' own sites 4

  1. Eliava institute producer checked 2026-11-15 · link not kept
  2. Adaptive phage therapeutics producer checked 2026-11-15 · link not kept
  3. Biomx producer checked 2026-11-15 · link not kept
  4. Microgen producer checked 2026-11-15 · link not kept